Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension

Journal of Hypertension

Volumn 30, Issue 12, 2012, Pages 2322-2330

  Kisaka, Tomohiko ^a   Ozono, Ryoji ^a   Ishida, Takafumi ^a   Higashi, Yukihito ^a   Oshima, Tetsuya ^a   Kihara, Yasuki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

aldosterone; essential hypertension; morbidity and mortality; renin; salt sensitivity

Indexed keywords

ALDOSTERONE; CREATININE; RENIN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

EID: 84870240654     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328359862d     Document Type: Article

References (39)

1. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120:893-901.
2. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345:1689-1697.
3. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009; 53:286-290.
4. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105:2212-2216.
5. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341:709-717.
7. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11-21.
8. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010; 31:1237-1247.
9. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007; 115:1754-1761.
10. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthelemy O, Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006; 114:2604-2610.
11. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
12. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med 1993; 329:616-619.
13. Rossi A, Baldo-Enzi G, Calabro A, Sacchetto A, Pessina AC, Rossi GP. The renin-angiotensin-aldosterone system and carotid artery disease in mild-to-moderate primary hypertension. J Hypertens 2000; 18:1401-1409.
14. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001; 37:429-432.
15. Ozono R, Matsuura H, Oshima T, Ishibashi K, Ishida M, Ishida T, et al. Modulation of target tissue response to angiotensin II and sodium sensitivity in Japanese patients with essential hypertension. Hypertens Res 1996; 19:141-145.
16. Komiya I, Yamada T, Takasu N, Asawa T, Akamine H, Yagi N, et al. An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system. J Hypertens 1997; 15:65-72.
17. Oshima T, Matsuura H, Kido K, Matsumoto K, Fujii H, Masaoka S, et al. Intralymphocytic sodium and free calcium and plasma renin in essential hypertension. Hypertension 1988; 12:26-31.
18. Oshima T, Matsuura H, Kido K, Matsumoto K, Shingu T, Otsuki T, et al. Factors determining sodium chloride sensitivity of patients with essential hypertension: evaluation by multivariate analysis. J Hypertens 1989; 7:223-227.
19. Ishibashi K, Oshima T, Matsuura H, Watanabe M, Ishida M, Ishida T, et al. Effects of age and sex on sodium chloride sensitivity: association with plasma renin activity. Clin Nephrol 1994; 42:376-380.
20. Kaplan NM, Kem DC, Holland OB, Kramer NJ, Higgins J, Gomez-Sanchez C. The intravenous furosemide test: a simple way to evaluate renin responsiveness. Ann Intern Med 1976; 84:639-645.
21. Gordon RD, Klemm SA, Stowasser M, Tunny TJ, Storie WJ, Rutherford JC. How common is primary aldosteronism? Is it the most frequent cause of curable hypertension? J Hypertens Suppl 1993; 11:S310-S311.
22. Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nat Rev Endocrinol 2010; 6:83-93.
23. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
24. Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G, et al. Within-patient reproducibility of the aldosterone:renin ratio in primary aldosteronism. Hypertension 2010; 55:83-89.
25. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'nonselective' screening of hypertensive patients. J Hypertens 2003; 21:2149-2157.
26. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49:846-856.
27. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159-1164.
28. Grim CE, Cowley AW Jr, Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension 2005; 45:766-772.
29. Meneton P, Galan P, Bertrais S, Heudes D, Hercberg S, Menard J. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged caucasian populations. J Hum Hypertens 2008; 22:550-558.
30. Lieb W, Larson MG, Benjamin EJ, Yin X, Tofler GH, Selhub J, et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation 2009; 119:37-43.
31. Kainouchi M, Matsuura H, Shingu T, Inoue I, Ishida T, Ozono R, et al. Time-course of changes in intracellular cations and blood pressure with salt loading in patients with essential hypertension. J Hypertens Suppl 1991; 9:S302-S303.
32. Higashi Y, Oshima T, Ozono R, Nakano Y, Matsuura H, Kambe M, Kajiyama G. Nocturnal decline in blood pressure is attenuated by NaCl loading in salt-sensitive patients with essential hypertension: noninvasive 24-h ambulatory blood pressure monitoring. Hypertension 1997; 30:163-167.
33. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-35.
34. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 2009; 119:3078-3084.
35. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997; 350:1734-1737.
36. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama Study. Arch Intern Med 2003; 163:361-366.
37. Osmond JM, Rigsby CS, Dorrance AM. Is the mineralocorticoid receptor a potential target for stroke prevention? Clin Sci (Lond) 2008; 114:37-47.
38. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31:451-458.
39. MacLeod AB, Vasdev S, Smeda JS. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopriltreated hypertensive rats. Stroke 1997; 28:1821-1828; discussion 1829.